|本期目录/Table of Contents|

[1]梁菁菁,蒋 戚.11β-羟基类固醇脱氢酶抑制剂的临床应用[J].医学研究与战创伤救治(原医学研究生学报),2012,14(02):149-151.
点击复制

11β-羟基类固醇脱氢酶抑制剂的临床应用()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第14卷
期数:
2012年02期
页码:
149-151
栏目:
综述
出版日期:
2012-03-20

文章信息/Info

Title:
-
文章编号:
1672-271X(2012)02-0149-03
作者:
梁菁菁1; 蒋 戚2
1.211222 江苏南京，解放军73017部队; 2.200433 上海，第二军医大学研究生管理大队临床6 队
Author(s):
-
关键词:
11β-羟基类固醇脱氢酶; 11β-羟基类固醇脱氢酶抑制剂; 糖尿病; 肥胖
Keywords:
-
分类号:
R969;R587.1
DOI:
-
文献标志码:
A
摘要:
近年来，有研究发现11β-羟基类固醇脱氢酶可能参与了以2型糖尿病、肥胖、胰岛素抵抗、高血压等为主要表现的代谢综合征的病理生理过程，选择性的11β-羟基类固醇脱氢酶抑制剂很有可能成为治疗糖尿病、肥胖症等疾病的新药。本文就11β-HSD的作用、11β-HSD抑制剂种类与作用等作一综述。
Abstract:
-

参考文献/References:

[1]Edwards CR,Stewart PM,Burt D,et al.Localisation of 11 beta-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor[J].Lancet,1988,2(8618):986-989.
[2]Crandall J,Schade D,Ma Y,et al.The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes[J].J Gerontol A Biol Sci Med Sci,2006,61(10):1075-1081.
[3]Tomlinson JW,Walker EA,Bujalska IJ,et al.11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response[J].Endocr Rev,2004,25(5):831-866.
[4]Mondok A,Varga I,Glaz E,et al.11beta-hydroxysteroid dehydrogenase activity in acromegalic patients with normal or impaired carbohydrate metabolism[J].Steroids,2009,74(9):725-729.
[5]Agarwal AK,Mune T,Monder C,et al.NAD(+)-dependent isoform of 11 beta-hydroxysteroid dehydrogenase.Cloning and characterization of cDNA from sheep kidney[J].J Biol Chem,1994,269(42):25959-25962.
[6]Stewart PM,Whorwood CB,Mason JI.Type 2 11 beta-hydroxysteroid dehydrogenase in foetal and adult life[J].J Steroid Biochem Mol Biol,1995,55(5-6):465-471.
[7]Stewart PM,Whorwood CB.11 beta-Hydroxysteroid dehydrogenase activity and corticosteroid hormone action[J].Steroids,1994,59(2):90-95.
[8]Seckl JR,Meaney MJ.Glucocorticoid programming[J].Ann N Y Acad Sci,2004,1032(12):63-84.
[9]Rabbitt EH,Ayuk J,Boelaert K,et al.Abnormal expression of 11 beta-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation[J].Oncogene,2003,22(11):1663-1667.
[10]Suzuki K,Nakajima H,Ikeda K,et al.IL-4-Stat6 signaling induces tristetraprolin expression and inhibits TNF-alpha production in mast cells[J].J Exp Med,2003,198(11):1717-1727.
[11] Stulnig TM,Waldhusl W.11beta-Hydroxysteroid dehydrogenase type 1 in obesity and type 2 diabetes[J].Diabetologia,2004,47(1):1-11.
[12]Davani B,Khan A,Hult M,et al.Type 1 11beta-hydroxysteroid dehydrogenase mediates glucocorticoid activation and insulin release in pancreatic islets[J].J Biol Chem,2000,275(45):34841-34844.
[13]Veilleux A,Rhéaume C,Daris M,et al.Omental adipose tissue type 1 11 beta-hydroxysteroid dehydrogenase oxoreductase activity,body fat distribution,and metabolic alterations in women[J].J Clin Endocrinol Metab,2009,94(9):3550-3557.
[14]Kannisto K,Pietilinen KH,Ehrenborg E,et al.Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins[J].J Clin Endocrinol Metab,2004,89(9):4414-4421.
[15]Stimson RH,Andrew R,McAvoy NC,et al.Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition[J].Diabetes,2011,60(3):720-725.
[16]Nuotio-Antar AM,Hachey DL,Hasty AH.Carbenoxolone treatment attenuates s ymptoms of metabolic syndrome and atherogenesis in obese,hyperlipidemic mice[J].Am J Physiol Endocrinol Metab,2007,293(6):E1517-1528.
[17]Tomlinson JW,Sherlock M,Hughes B,et al.Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis[J].J Clin Endocrinol Metab,2007,92(3):857-864.
[18]Sandeep TC,Yau JL,MacLullich AM,et al.11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics[J].Proc Natl Acad Sci USA,2004,101(17):6734-6739.
[19]Hult M,Shafqat N,Elleby B,et al.Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons[J].Mol Cell Endocrinol,2006,248(1-2):26-33.
[20]Wamil M,Seckl JR.Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target[J].Drug Discov Today,2007,12(13-14):504-520.
[21]Feng Y,Huang SL,Dou W,et al.Emodin,a natural product,selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice[J].Br J Pharmacol,2010,161(1):113-126.
[22]Hermanowski-Vosatka A,Balkovec JM,Cheng K,et al.11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice[J].J Exp Med,2005,202(4):517-527.
[23]Véniant MM,Hale C,Komorowski R,et al.Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice[J].Diabetes Obes Metab,2009,11(2):109-117.
[24]Lloyd DJ,Helmering J,Cordover D,et al.Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes,dyslipidaemia and atherosclerosis[J].Diabetes Obes Metab,2009,11(7):688-699.
[25]孙国栋，范茂丹，周 杨，等.不同糖代谢状态疗养员动脉硬化检测结果及影响因素分析[J].东南国防医药,2011,13(3):236-238.

相似文献/References:

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2012-03-20